Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"LAMA2"”.
-
Characterizing and targeting fibrosis in a model of Lama2-related muscular dystrophy
Laminin-deficient congenital muscular dystrophy 1A (MDC1A) is the second most prevalent congenital muscular dystrophy (CMD) and is due to a defect in the alpha chain of the basement membrane protein laminin-211. This protein serves as the vital link between the muscle cell membrane (sarcolemma) and …
-
The role of recombinant human laminin-111 in adhesion-signaling and glycosylation in laminin-⍺2 deficient muscle
LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is a rare and severe neuromuscular disease characterized by progressive muscular degeneration. LAMA2-CMD is caused by mutations in LAMA2 which encodes for the laminin-α2 protein. Loss of laminin-α2 results in the absence of laminin-211/221, an …
-
LAMININ AS A THERAPEUTIC TARGET FOR MUSCULAR DYSTROPHY
… MDs are Duchenne muscular dystrophy (DMD) and LAMA2-related Congenital Muscular Dystrophy (LAMA2-CMD). DMD is caused by mutations in the gene that encodes for dystrophin and LAMA2-CMD is caused by mutations in the gene that encodes for laminin-α2. Both mutations result in structural disruption …
-
Muscle Fiber Characterization of the DyW Animal Model of Laminin Alpha 2 Congenital Muscular Dystrophy
Laminin-α2 congenital muscular dystrophy (LAMA2-CMD) is a rare disease affecting children as early as birth. It is a result of mutations in the LAMA2 gene responsible for coding the laminin alpha 2 chain. The alpha chain is one-third of an essential protein and significant component of the basement …
-
Production and purification of recombinant human laminin-111 for pre-clinical testing in a murine model of laminin-α2 deficient congenital muscular dystrophy
… α2-deficient congenital muscular dystrophy (LAMA2-CMD) is a fatal genetic neuromuscular disease that currently has no cure. Patients with LAMA2-CMD suffer from muscle wasting, respiratory issues, and neurological effects until eventual death at a premature age due to loss of the adult …
-
Muscular dystrophy: from mouse models to small molecule therapies
… congenital muscular dystrophy (LAMA2-CMD), respectively. Our results show that treatment with sunitinib prevents DMD-related cardiomyopathy progression by improving cardiac histopathology and function in a mouse model of DMD, and treatment with vemurafenib improves skeletal …
-
Laminin-111 Protein Therapy for the Treatment of Merosin Deficient Congenital Muscular Dystrophy Type 1A
… serious neuromuscular disease caused by a mutant LAMA2 gene. Loss of function of the LAMA2 gene leads to a deficiency of laminin-211/221, which are crucial to the basal lamina and the integrity of skeletal muscle. Currently, there is no cure or effective treatment for MDC1A. These patients have a …
-
Enhanced alpha7beta1 integrin prevents muscle disease in a mouse model of congenital muscular dystrophy
… disease which results from mutations in the LAMA2 gene leading to either a complete or partial absence of the protein laminin α2. The loss of laminin α2 protein in turn leads to a failure to produce laminin 211 and laminin 221. Laminin 211 is the major laminin component of the …
-
Fibronectin and Laminin, extracellular matrix proteins, have an origin in mesoderm tissue and promote anterior neural tube closure in zebrafish
… the mRNA for extracellular matrix genes lama1, lama2, lamb1a, lamc1, fn1a, and fn1b were all expressed in mesoderm tissue adjacent to the developing neural tube. Further, expression of these lam and fn genes in the mesoderm occurred during neurulation. This suggests that one role of mesoderm in …
-
Congenital muscular dystrophy with laminin α2 chain-deficiency. Initiation of disease and development of treatment
… is a muscle disease caused bymutations in the LAMA2 gene, encoding the basement membrane protein lamininα2 chain. MDC1A patients exhibit neonatal onset of muscle weakness, progressivemuscle wasting and hypotonia, joint contractures that mostly affect elbows, hips,knees and ankles along with …
-
Congenital muscular dystrophy: early pathology and combinatorial treatment strategies
… to thrive. MDC1A results from mutation of the LAMA2 gene, which encodes for the laminin-a2 chain of laminin 211. Laminin 211 is an extracellular matrix protein predominantly expressed in the basal lamina of skeletal muscle and Schwann cells. As laminin 211 has multiple binding partners in the …
-
Efficacy of losartan and growth hormone combinatorial therapy in DyW mice
… near birth. MDC1A is caused by a mutation in the LAMA2 gene which encodes a protein called laminin-2. The clinical manifestations of MDC1A include profound muscle weakness, muscle hypotonia, loss of independent ambulation, and respiratory failure. There is still no cure or effective treatment …
-
Growth gone awry: exploring the role of embryonic liver development genes in HCV induced cirrhosis and hepatocellular carcinoma
… with overexpression of c-MET and loss of STAT3, LAMA2, FGFR2, CITED2, KIT, SMAD7, GATA6, ERBB2, and NOTCH2.
-
A New Congenital Mouse Model to Study Laminin Protein Therapy for Muscular Dystrophy
… cardiac muscle basal lamina; mutations in the LAMA2 gene cause the loss of these laminin isoforms. This absence of laminin-211/221 in MDC1A reduces the capacity for myofiber adhesion, loss of sarcolemmal integrity and subsequently the ability of the skeletal muscle syncytium to generate force …